These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 11966649)

  • 1. Acute renal artery occlusion in a 15-year-old girl taking oral contraceptives.
    Saint F; Quintela R; Salomon L; Cicco A; Olsson E; Chopin D; Abbou CC
    BJU Int; 2002 May; 89(7):787-8. PubMed ID: 11966649
    [No Abstract]   [Full Text] [Related]  

  • 2. Comment on 'Statement on combined hormonal contraceptives containing third- or fourth-generation progestogens or cyproterone acetate, and the associated risk of thromboembolism'.
    Terplan M; Zuckerman D
    J Fam Plann Reprod Health Care; 2013 Oct; 39(4):304. PubMed ID: 24062505
    [No Abstract]   [Full Text] [Related]  

  • 3. Comment on 'Statement on combined hormonal contraceptives containing third- or fourth-generation progestogens or cyproterone acetate, and the associated risk of thromboembolism': author's response.
    Bitzer J
    J Fam Plann Reprod Health Care; 2013 Oct; 39(4):304-5. PubMed ID: 24062506
    [No Abstract]   [Full Text] [Related]  

  • 4. Statement on combined hormonal contraceptives containing third- or fourth-generation progestogens or cyproterone acetate, and the associated risk of thromboembolism.
    Bitzer J; Amy JJ; Beerthuizen R; Birkhäuser M; Bombas T; Creinin M; Darney PD; Vicente LF; Gemzell-Danielsson K; Imthurn B; Jensen JT; Kaunitz AM; Kubba A; Lech MM; Mansour D; Merki G; Rabe T; Sedlecki K; Serfaty D; Seydoux J; Shulman LP; Sitruk-Ware R; Skouby SO; Szarewski A; Trussell J; Westhoff C
    J Fam Plann Reprod Health Care; 2013 Jul; 39(3):156-9. PubMed ID: 23585363
    [No Abstract]   [Full Text] [Related]  

  • 5. Statement on combined hormonal contraceptives containing third- or fourth-generation progestogens or cyproterone acetate, and the associated risk of thromboembolism.
    Bitzer J; Amy JJ; Beerthuizen R; Birkhäuser M; Bombas T; Creinin M; Darney PD; Vicente LF; Gemzell-Danielsson K; Imthurn B; Jensen JT; Kaunitz AM; Kubba A; Lech MM; Mansour D; Merki G; Rabe T; Sedlecki K; Serfaty D; Seydoux J; Shulman LP; Sitruk-Ware R; Skouby SO; Szarewski A; Trussell J; Westhoff C
    Eur J Contracept Reprod Health Care; 2013 Jun; 18(3):143-7. PubMed ID: 23578274
    [No Abstract]   [Full Text] [Related]  

  • 6. What is the risk of venous thromboembolism (VTE) among women taking third-generation oral contraceptives (OCs) in comparison with those taking contraceptives containing levonorgestrel?
    Meurer LN; Slawson JG
    J Fam Pract; 2001 Feb; 50(2):108. PubMed ID: 11219554
    [No Abstract]   [Full Text] [Related]  

  • 7. Development of diabetes mellitus and hypertension due to aggravation of insulin resistance after estrogen--progestogen in HAIR-AN syndrome.
    Vaidya RA; Shringi MS; Vaidya AB; Gogate JG
    J Assoc Physicians India; 1997 Nov; 45(11):883-4. PubMed ID: 11229194
    [No Abstract]   [Full Text] [Related]  

  • 8. [Oral contraceptives, risks and hazards].
    Revuz J
    Ann Dermatol Venereol; 2014 Jan; 141(1):5-6. PubMed ID: 24461087
    [No Abstract]   [Full Text] [Related]  

  • 9. The safety profile of Yasmin is similar to other combined oral contraceptives.
    Cronin M; Korner P
    Clin Appl Thromb Hemost; 2008 Apr; 14(2):245-6. PubMed ID: 18372279
    [No Abstract]   [Full Text] [Related]  

  • 10. Acute myocardial infarction associated with Yasmin oral contraceptive.
    Ortí G; Mira Y; Vaya A
    Clin Appl Thromb Hemost; 2007 Jul; 13(3):336-7. PubMed ID: 17636199
    [No Abstract]   [Full Text] [Related]  

  • 11. Diane-35 (cyproterone acetate): safety concerns.
    Wooltorton E
    CMAJ; 2003 Feb; 168(4):455-6. PubMed ID: 12591790
    [No Abstract]   [Full Text] [Related]  

  • 12. [Oral contraceptives and thromboembolism (author's transl)].
    Sato K; Ogino M; Nakabayashi M; Sakamoto S
    Kokyu To Junkan; 1978 Mar; 26(3):212-20. PubMed ID: 349637
    [No Abstract]   [Full Text] [Related]  

  • 13. Valuable scientific contributions of Brambilla and Martelli.
    Schweinfurth H; Reimann R; Wolff T
    Mutat Res; 2004 May; 566(3):263-5; author reply 267-8. PubMed ID: 15082241
    [No Abstract]   [Full Text] [Related]  

  • 14. Papillophlebitis associated with the use of oral contraceptive: a case report.
    Eski Yücel O; Güngor I; Gül A; Turgut M; Aritürk N
    Gynecol Endocrinol; 2015; 31(8):601-3. PubMed ID: 26291803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of two kinds of different combined oral contraceptives use on bone mineral density in adolescent women.
    Gai L; Jia Y; Zhang M; Gai P; Wang S; Shi H; Yu X; Liu Y
    Contraception; 2012 Oct; 86(4):332-6. PubMed ID: 22364818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Which pill?
    Br Med J (Clin Res Ed); 1983 Dec; 287(6407):1796-7. PubMed ID: 6416597
    [No Abstract]   [Full Text] [Related]  

  • 17. [Syndrome due to estrogen-progestogens in a worker engaged in the production of contraceptive agents].
    Gambini G; Farina G; Arbosti G
    Med Lav; 1976; 67(2):152-7. PubMed ID: 1021708
    [No Abstract]   [Full Text] [Related]  

  • 18. [Lipid metabolism disorders and increased vascular risk due to contraceptive steroids].
    Basdevant A; de Lignieres B; Mauvais-Jarvis P
    Nouv Presse Med; 1976 Apr; 6(17):1469-72. PubMed ID: 1025526
    [No Abstract]   [Full Text] [Related]  

  • 19. [Hormonal contraception and cancer risk].
    Ebeling K; Göretzlehner G
    Z Arztl Fortbild (Jena); 1985; 79(9):365-7. PubMed ID: 4024671
    [No Abstract]   [Full Text] [Related]  

  • 20. Hormonal contraceptives, progestogens only.
    IARC Monogr Eval Carcinog Risks Hum; 1999; 72():339-97. PubMed ID: 10533178
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.